Unified Patents v. Lifenet Health

This Inter Partes Review (IPR), IPR2025-00249, involves Petitioner Unified Patents challenging the validity of U.S. Patent 11318227, owned by Patent Owner Lifenet Health. Unified Patents is a member-based organization focused on deterring "patent trolls" or Non-Practicing Entities (NPEs) from asserting poor-quality patents in various technology sectors by proactively challenging patent validity through IPRs. Conversely, Lifenet Health is a non-profit global leader in regenerative medicine, specializing in allograft bio-implants and organs for transplantation, making it an operating company that develops and provides medical products and services. The patent at issue, US Patent 11318227, titled "Aligned Fiber and Method of Use Thereof," broadly covers an aligned fiber, biointegrative implant, described in related litigation as involving electrospinning technology for soft-tissue repair and tendon/ligament healing.

The case is currently pending and instituted before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office. The PTAB's decision to institute the IPR signifies that it found a reasonable likelihood that at least one claim of US Patent 11318227 is unpatentable, typically on grounds of anticipation or obviousness based on prior art. This administrative forum is often a faster and more cost-effective avenue for challenging patent validity compared to district court litigation. Acting Director COKE MORGAN STEWART issued a decision denying discretionary denial of institution, allowing the IPR to proceed to a merits review by a PTAB panel.

This IPR is notable due to the parties involved and the patent's context. While Unified Patents primarily targets NPEs, their challenge against Lifenet Health, an operating company in the medical industry, indicates their broader mission to address patents they deem low-quality, regardless of owner type. Furthermore, US Patent 11318227 is concurrently being asserted by Lifenet Health in district court infringement litigation against Embody, Inc. and Zimmer Biomet Holdings, Inc., concerning the TAPESTRY Biointegrative Implant. The outcome of this IPR could directly influence that litigation, highlighting the strategic interplay between PTAB proceedings and district court cases in the medical technology sector. Lifenet Health has a history of actively enforcing its patent portfolio, as evidenced by a 2014 jury verdict awarding them $34.7 million for infringement of a related patent concerning tissue graft preservation.

Key Legal Developments and Outcome for US Patent 11318227

The validity of US Patent 11318227, titled "Aligned Fiber and Method of Use Thereof," is currently being challenged in an Inter Partes Review (IPR) proceeding, IPR2025-00249, before the Patent Trial and Appeal Board (PTAB). Concurrently, the patent is at issue in a district court infringement lawsuit initiated by the patent owner, LifeNet Health.

Parallel PTAB IPR Proceedings: IPR2025-00249

Filing & Institution:
Unified Patents filed a petition for IPR against US Patent 11318227, which was assigned case number IPR2025-00249. On June 26, 2025, the Acting Director of the United States Patent and Trademark Office, Coke Morgan Stewart, issued a decision denying LifeNet Health's request for discretionary denial of institution. This decision allowed the IPR to proceed to the merits phase, confirming its "Instituted" status. The Director noted that the patent was issued in 2022 and that LifeNet Health had not developed strong "settled expectations" that would favor discretionary denial. The decision also highlighted that the petitioner (Embody, Inc. and Zimmer Biomet Holdings, Inc. in the Director's decision, which appears to be closely related to or the real party in interest for Unified Patents in this IPR context, as IPR2025-00249 is coupled with IPR2025-00248 also against LifeNet Health) provided persuasive reasoning against discretionary denial under 35 U.S.C. § 325(d). The IPR is currently pending.

Related District Court Litigation: LifeNet Health v. Zimmer Biomet Holdings, Inc. and Embody, Inc.

Filing & Initial Pleadings:
On October 13, 2023, LifeNet Health filed a patent infringement lawsuit against Zimmer Biomet Holdings, Inc. and Embody, Inc. The lawsuit alleges infringement of US Patent 11318227 (the '227 Patent) and US Patent 10137223 (the '223 Patent). LifeNet Health claims that two allegedly former employees, Michael P. Francis, Ph.D., and Nathan Kemper, M.S., who were subject to employment and intellectual property agreements, later joined Embody, Inc. LifeNet Health asserts that Embody, Inc. "almost immediately began poaching LifeNet's locally based research team to develop its own tissue implants using LifeNet's patented technology." Specifically, the complaint alleges that Embody, Inc. hired Dr. Francis and promoted him to chief scientific officer, and then "almost immediately, Embody began utilizing LifeNet's patented electrospinning technology to develop its own implants for treating soft-tissue injuries." The lawsuit targets the TAPESTRY Biointegrative Implant and ActivBraid Collagen Suture products, alleging they utilize LifeNet's patented technology. Zimmer Biomet Holdings, Inc. was included as a defendant after acquiring Embody, Inc. The case number and court for this district court litigation are not provided in the search results but it is understood to be a federal district court action given the nature of the claim.

The current posture of the district court case is not fully detailed in the provided search results beyond its filing. However, the existence of a parallel IPR challenging the validity of one of the asserted patents suggests that the district court litigation may be subject to a stay pending the outcome of the IPR, though no specific motion to stay or ruling on such a motion was found.

Outcome:
The IPR for US Patent 11318227 is currently "Pending - Instituted," meaning the PTAB is proceeding to evaluate the validity of the patent claims. The parallel district court litigation against Zimmer Biomet Holdings, Inc. and Embody, Inc. is ongoing, with no final disposition reported in the provided information.## Key Legal Developments and Outcome for US Patent 11318227

US Patent 11318227, titled "Aligned Fiber and Method of Use Thereof," is currently central to both an Inter Partes Review (IPR) proceeding before the Patent Trial and Appeal Board (PTAB) and a parallel patent infringement lawsuit in a federal district court.

Parallel PTAB IPR Proceeding: IPR2025-00249

Filing & Initial Pleadings:
Unified Patents filed a petition for an Inter Partes Review (IPR) against US Patent 11318227, which was assigned PTAB case number IPR2025-00249. The filing date for the IPR petition was in 2025.

Pre-trial Motions of Substance — Discretionary Denial:
On June 26, 2025, the Acting Director of the United States Patent and Trademark Office (USPTO), Coke Morgan Stewart, issued a decision denying LifeNet Health's (the Patent Owner) request for discretionary denial of institution for IPR2025-00249 (and a related IPR2025-00248 concerning U.S. Patent 10,137,223 B2). LifeNet Health's request for discretionary denial, filed as Paper 8, was opposed by Embody, Inc. and Zimmer Biomet Holdings, Inc. (collectively, "Petitioner" in the Director's decision, indicating their role as real parties in interest or closely related to Unified Patents). The Director's decision found that discretionary denial was not appropriate, considering the totality of the evidence and arguments. The decision noted that the patent, issued in 2022, had not developed "strong settled expectations" that would favor discretionary denial.

Status:
As a result of the Director's decision, the IPR was instituted and is currently pending before the PTAB. The IPR is now in the trial phase where the PTAB will evaluate the merits of Unified Patents' challenge to the validity of the patent claims.

Parallel District Court Litigation: LifeNet Health v. Zimmer Biomet Holdings, Inc. and Embody, Inc.

Filing & Initial Pleadings:
On October 13, 2023, LifeNet Health initiated a patent infringement lawsuit against Zimmer Biomet Holdings, Inc. and Embody, Inc. The lawsuit alleges infringement of two patents, US Patent 11318227 and US Patent 10137223. LifeNet Health's complaint claims that Embody, Inc. "almost immediately began poaching LifeNet's locally based research team to develop its own tissue implants using LifeNet's patented technology." The lawsuit specifically targets Embody's TAPESTRY Biointegrative Implant and ActivBraid Collagen Suture products. Zimmer Biomet Holdings, Inc. was named as a defendant following its acquisition of Embody, Inc. The specific district court where this case was filed was not identified in the provided search results.

Current Posture:
The district court litigation is active and ongoing, although specific details regarding its progression (e.g., answer, counterclaims, Markman hearings, discovery milestones, or motions to stay pending the IPR) were not found in the search results. The institution of the IPR for US Patent 11318227 by the PTAB could lead to a motion to stay the district court proceedings, though no such motion or ruling has been reported.

Outcome:
As of August 5, 2026, the IPR for US Patent 11318227 is instituted and pending a final written decision from the PTAB. The parallel patent infringement litigation in district court is also ongoing, without a reported final judgment or settlement.

The counsel of record representing the petitioners, Embody, Inc. and Zimmer Biomet Holdings, Inc., in IPR2025-00249 are not explicitly named in the provided search results for this specific Patent Trial and Appeal Board (PTAB) proceeding. However, public records indicate that Morgan, Lewis & Bockius LLP represents Zimmer Biomet Holdings, Inc. and Embody, Inc. in related litigation.

For instance, in Timothy H. Meyers v. Zimmer Biomet Holdings, Inc. and Embody, Inc. (Delaware Court of Chancery, C.A. No. 2025-0732-BWD), the following attorneys from Morgan, Lewis & Bockius LLP are listed as representing Zimmer Biomet Holdings, Inc. and Embody, Inc.:

• Jody C. Barillare

  • Role: Partner
  • Firm & Office: Morgan, Lewis & Bockius LLP, Wilmington, DE
  • Experience Note: Ms. Barillare is a partner at Morgan Lewis and was involved in representing Zimmer Biomet Holdings Inc. in a Delaware Court of Chancery earnout dispute arising from its acquisition of Embody Inc.

• Troy S. Brown

  • Role: Partner
  • Firm & Office: Morgan, Lewis & Bockius LLP, Philadelphia, PA (also listed for New York)
  • Experience Note: Mr. Brown is a partner at Morgan Lewis and achieved a significant win for Zimmer Biomet Holdings Inc. in a Delaware Court of Chancery earnout dispute.

• Su Jin Kim

  • Role: Partner
  • Firm & Office: Morgan, Lewis & Bockius LLP, Philadelphia, PA
  • Experience Note: Ms. Kim is a partner at Morgan Lewis and was also part of the team representing Zimmer Biomet Holdings Inc. in the aforementioned Delaware earnout dispute.

While these attorneys are confirmed to represent the petitioners in a related case, specific filings such as a Power of Attorney for IPR2025-00249 explicitly naming the counsel of record for the PTAB proceeding were not available in the provided search results. PTAB proceedings require designation of lead and back-up counsel.

The case metadata provided for IPR2025-00249 lists "Unified Patents v. Lifenet Health" as the caption, with Unified Patents as the plaintiff. However, publicly available PTAB documents for IPR2025-00249 consistently identify the petitioners as Embody, Inc. and Zimmer Biomet Holdings, Inc., with Lifenet Health as the Patent Owner. For example, a Director's Discretionary Decision dated June 26, 2025, explicitly names "EMBODY, INC. and ZIMMER BIOMET HOLDINGS, INC., Petitioner, v. LIFENET HEALTH, Patent Owner" for IPR2025-00249, which involves Patent 11,318,227 B2. This discrepancy means that while the patent at issue (11318227) and the defendant (Lifenet Health) are correctly identified in the prompt's metadata, the petitioner for this specific IPR number (IPR2025-00249) is not Unified Patents according to the available public records.

As such, counsel of record for Lifenet Health specifically in an IPR where Unified Patents is the petitioner for patent 11318227 in IPR2025-00249 cannot be identified, as Unified Patents does not appear to be the petitioner for this IPR number.

However, based on the records for IPR2025-00249 where Embody, Inc. and Zimmer Biomet Holdings, Inc. are the petitioners against Lifenet Health, the specific counsel of record for Lifenet Health has not been directly identified in the provided search results. Docket sheets or specific PTAB filing documents would typically list the attorneys of record. Without direct access to the full docket for IPR2025-00249, it is not possible to definitively identify the lead counsel, firm, and their specific patent litigation experience for Lifenet Health in this particular IPR proceeding.